Cyprotex Extends Time Dependent Inhibition Service to Include the Cytochrome P450 Isoform, CYP2B6

Cyprotex, a preclinical ADME Tox services company, has extended its time-dependent inhibition service to include the cytochrome P450 (CYP450) isoform, CYP2B6.

Cyprotex, a preclinical ADME Tox services company, has extended its time-dependent inhibition service to include the cytochrome P450 (CYP450) isoform, CYP2B6.
Inhibition of the various CYP450 isoforms, including CYP2B6, is one of the main causes of drug-drug interactions. Drug-drug interactions can cause otherwise safe medicines to accumulate in the body resulting in toxicity.
A US FDA update paper by Huang et al., 2008 (J Clin Pharmacol 48; 662-670) has highlighted the importance of CYP2B6 in clinical interactions and recommends that CYP2B6 should be investigated in vitro when assessing whether enzyme inhibition or induction has the potential to produce a drug interaction.
CYP450 inhibition can produce either reversible or irreversible drug-drug interactions. Time-dependent inhibition assays identify compounds which have the potential to form an irreversible drug-drug interaction. These types of drug-drug interactions, although less common,